Cargando…
Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) showed a benefit-risk profile superior to that of warfarin in atrial fibrillation (AF) patients with mild to moderate chronic kidney disease. However, the effectiveness and safety of NOACs in AF patients with end-stage renal disease (E...
Autores principales: | Li, Wenhao, Zhou, Yanxia, Chen, Siqi, Zeng, Dewang, Zhang, Haidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513185/ https://www.ncbi.nlm.nih.gov/pubmed/36176998 http://dx.doi.org/10.3389/fcvm.2022.1005742 |
Ejemplares similares
-
Direct Oral Anticoagulants vs. Vitamin K Antagonists in Atrial Fibrillation Patients at Risk of Falling: A Meta-Analysis
por: Gao, Xinxing, et al.
Publicado: (2022) -
Reappraisal of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2021) -
Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
por: Liao, Jo-Nan, et al.
Publicado: (2022) -
Off-Label Underdosing or Overdosing of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis
por: Wu, Xiaojuan, et al.
Publicado: (2021) -
Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016
por: Maura, Géric, et al.
Publicado: (2019)